Quantoom Biosciences

Greater access and autonomy through innovation in bioproduction

We are on a mission to remove the barriers to making mRNA-based vaccines & therapeutics,
at every stage from sequence up to mass production.

Who We Are

Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.

We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.

In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.

Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

Who We Are

Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.

We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.

In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.

Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

what we do

At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.

Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.

More specifically, we have developed:

A benchtop DNA system to amplify any linearized plasmid with the gene of interest as a base for RNA synthesisA benchtop research-grade RNA system for screening and to provide very small-scale batches of mRNA (typically µg-scale for pre-clinical applications)A small footprint GMP-grade RNA production system able to seamlessly scale up from clinical scale up to commercial mass production A Formulation system based on microfluidics to blend the RNA sequence in a LNP-based delivery vehicleSelected reagents that are critical to the process

what we do

At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.

Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.

More specifically, we have developed:

A benchtop DNA system to amplify any linearized plasmid with the gene of interest as a base for RNA synthesisA benchtop research-grade RNA system for screening and to provide very small-scale batches of mRNA (typically µg-scale for pre-clinical applications)A small footprint GMP-grade RNA production system able to seamlessly scale up from clinical scale up to commercial mass production A Formulation system based on microfluidics to blend the RNA sequence in a LNP-based delivery vehicleSelected reagents that are critical to the process

Our GMP-grade RNA Production System

We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.
Intensification & chaining: We can manufacture mRNA at a wide range of capacities thanks to our sequential-continuous production mode at milliliter-scale. This includes IVT and mRNA purification, to deliver purified naked RNATunable generic process: We have redesigned the production process and validated it for mRNA and saRNA. The process is adaptable and able to take sequence specificities into consideration.

These features deliver a set of benefits for mRNA drug developers;

1

No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development

2

Single small footprint system that integrates all process steps - no need to invest in a suite of equipment

3

Generic process that is adaptable to your specific RNA construct both for transcription and purification, with polishing options

4

Reduced CoGs thanks to minimal labor & RNA expertise required

5

In vivo validated with multiple RNA constructs to de-risk your product development

Key numbers:

Up to 20 g per day (5 kg per year) of purified mRNA per system

Up to 100 million doses (50 µg) per year

Our GMP-grade RNA Production System

We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.
Intensification & chaining: We can manufacture mRNA at a wide range of capacities thanks to our sequential-continuous production mode at milliliter-scale. This includes IVT and mRNA purification, to deliver purified naked RNATunable generic process: We have redesigned the production process and validated it for mRNA and saRNA. The process is adaptable and able to take sequence specificities into consideration.

These features deliver a set of benefits for mRNA drug developers;

1

No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development

2

Single small footprint system that integrates all process steps - no need to invest in a suite of equipment

3

Generic process that is adaptable to your specific RNA construct both for transcription and purification, with polishing options

4

Reduced CoGs thanks to minimal labor & RNA expertise required

5

In vivo validated with multiple RNA constructs to de-risk your product development

Key numbers:Up to 20 g per day (5 kg per year) of purified mRNA per systemUp to 100 million doses (50 µg) per year

What we can help you with today​

1

RNA Research, Development & Production from sequence to clinical batch production

2

Early adopter partner agreement for our RNA Production System offering preferential conditions & services

3

Strategic collaboration to accelerate mutual interests

What makes us different

We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we doProcess intensification and chaining with automated operations in a small footprint systemIntegration of critical components into our supply chain (such as DNA synthesis)Clinical-validation of platforms with (pre-) clinical studies, proving comparabilityAccess - Lower entry barriers to drug development and productionOpen access, independent licensing of desired drug productSecured supply of critical input materials for your operationsLow set-up and routine cost requirementsEased technology transfer, limited know-how requirements to operate the platformsAutonomy - Self-sufficient production up to commercial scaleScalability by design to seamlessly grow from lab to mass productionHighly flexible platforms fit for a wide range of therapeutic applicationsGMP certified allowing production for clinical studies and commercialization Clinically-validated systems to focus your efforts on drug development

What makes us different

We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we doProcess intensification and chaining with automated operations in a small footprint systemIntegration of critical components into our supply chain (such as DNA synthesis)Clinical-validation of platforms with (pre-) clinical studies, proving comparabilityAccess - Lower entry barriers to drug development and productionOpen access, independent licensing of desired drug productSecured supply of critical input materials for your operationsLow set-up and routine cost requirementsEased technology transfer, limited know-how requirements to operate the platformsAutonomy - Self-sufficient production up to commercial scaleScalability by design to seamlessly grow from lab to mass productionHighly flexible platforms fit for a wide range of therapeutic applicationsGMP certified allowing production for clinical studies and commercialization Clinically-validated systems to focus your efforts on drug development

Enabling more organisations to explore a wider range of
product development opportunities to get to treatments faster.

Enabling more organisations to explore a wider range of product development opportunities to get to treatments faster.

Our Team

Our team consists of international experts whose talent, experience and commitment
make the company a key player in therapeutic development and biomanufacturing.

Management Team

José Castillo

Chief Executive Officer
(and Univercells Co-Founder)

Kristof Vandekerckhove

Chief Scientific Officer & Head of Research BE

Yves Ghislain

Head of Technical Development & Operations

Conor Cahill

Head of Product Development

Irina Gbalou

Head of Research FR

Guillaume Roelandts

Head of Commercial Operations

Rachana Talwar

Head of PMO & Chief of Staff

Strategic & Scientific Advisory Board

Pierre Morgon (board member)Jean-Paul Prieels (board member)Michel De WildeAndrin OswaldBeate Kampmann

NEws & views

Press Releases

New agreement paves way for development of first African-owned COVID-19 vaccine

Read More

Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

Read More

Quantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics

Read More

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

Read More

Relevant resources

mRNA, a Revolution in Biomedicine The tangled history of mRNA vaccinesEvolution of the market for mRNA technologySee All
News & Views